Linked Data API

Show Search Form

Search Results

1124588
star this property registered interest false more like this
star this property date less than 2019-05-02more like thismore than 2019-05-02
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Prescriptions: Fees and Charges more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 30 April 2019 to Question 245660 on Prescriptions: Fees and Charges, what the annual cost is to the NHS Business Services Authority's Loss Recovery Service of (a) checking prescription form exemption declarations, (b) issuing Penalty Charge Notices and (c) managing associated customer contact. more like this
star this property tabling member constituency Knowsley more like this
star this property tabling member printed
Mr George Howarth more like this
star this property uin 250443 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-14more like thismore than 2019-05-14
star this property answer text <p>In 2018-19 the cost to the NHS Business Services Authority for the running of the Prescription Exemption Checking Service which includes, checking prescription form exemption declarations, issuing Penalty Charge Notices and managing associated customer contact was £8.41 million.</p> more like this
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property question first answered
less than 2019-05-14T15:26:42.82Zmore like thismore than 2019-05-14T15:26:42.82Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
481
star this property label Biography information for Sir George Howarth more like this
1124682
star this property registered interest false more like this
star this property date less than 2019-05-03more like thismore than 2019-05-03
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Speech Therapy: Children more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, whether Public Health England has plans to issue guidance to (a) parents and (b) carers on (i) identifying need for and (ii) access to speech, language and communication services for children . more like this
star this property tabling member constituency Swansea West more like this
star this property tabling member printed
Geraint Davies more like this
star this property uin 250735 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-14more like thismore than 2019-05-14
star this property answer text <p>Public Health England (PHE) is working in partnership with the Department for Education to produce evidence-based resources and tools to support health visitors, early years practitioners and parents/carers in identifying and supporting children’s early speech, language and communication (SLC) needs through training guidance and an enhanced early language assessment tool. The assessment tool will incorporate parent resources to support family understanding of SLC in their children and will be rolled out from April 2020.</p><p> </p><p>Alongside this work, PHE is developing a model SLC pathway for children under five. This will ensure that professionals working with families are able to help them support their child’s SLC and how to access support if needed. The pathway will be published by September 2019.</p> more like this
star this property answering member constituency Gosport more like this
star this property answering member printed Caroline Dinenage more like this
star this property question first answered
less than 2019-05-14T16:09:38.827Zmore like thismore than 2019-05-14T16:09:38.827Z
star this property answering member
4008
star this property label Biography information for Caroline Dinenage more like this
star this property tabling member
155
star this property label Biography information for Geraint Davies more like this
1124720
star this property registered interest false more like this
star this property date less than 2019-05-03more like thismore than 2019-05-03
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Idiopathic Pulmonary Fibrosis more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what steps he is taking to improve (a) early diagnosis and (b) treatment of idiopathic pulmonary fibrosis. more like this
star this property tabling member constituency Stevenage more like this
star this property tabling member printed
Stephen McPartland more like this
star this property uin 250788 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-15more like thismore than 2019-05-15
star this property answer text <p>The United Kingdom Rare Disease Strategy, published in 2013, sets out our commitment to raising awareness about all rare diseases including idiopathic pulmonary fibrosis (IPF) and our strategic vision for improving the lives of all those affected. The Strategy promotes improvements to ensure that people living with a rare disease receive high-quality care.</p><p>The Government recognizes the need for awareness raising and training of health care professionals for rare diseases. This is being taken forward through the work of the UK Rare Diseases Policy Board and NHS England’s Rare Diseases Implementation plan, which commits NHS England to engaging with the Royal College of General Practitioners (GPs) and the Nursing and Midwifery Council on opportunities for GPs and health visitors to recognise and facilitate earlier diagnosis of rare diseases.</p><p>There are limited drug treatment options for IPF and two drugs, Pirfenidone and Nintedanib, are commissioned following National Institute for Health and Care Excellence Technology Appraisals. Alongside this, the Department funds research into rare diseases such as IPF through the National Institute for Health Research (NIHR).</p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property question first answered
less than 2019-05-15T16:35:47.667Zmore like thismore than 2019-05-15T16:35:47.667Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4093
star this property label Biography information for Stephen McPartland more like this
1124729
star this property registered interest false more like this
star this property date less than 2019-05-03more like thismore than 2019-05-03
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Speech Therapy: Children and Young People more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what discussions he has had with NHS Clinical Commissioners on the importance of joint commissioning services for children and young people with speech, language and communication needs. more like this
star this property tabling member constituency Swansea West more like this
star this property tabling member printed
Geraint Davies more like this
star this property uin 250739 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-14more like thismore than 2019-05-14
star this property answer text <p>The Department has had no discussions with the organisation NHS Clinical Commissioners on joint commissioning of services for children and young people with speech, language and communication needs.</p> more like this
star this property answering member constituency Gosport more like this
star this property answering member printed Caroline Dinenage more like this
star this property question first answered
less than 2019-05-14T16:06:09.57Zmore like thismore than 2019-05-14T16:06:09.57Z
star this property answering member
4008
star this property label Biography information for Caroline Dinenage more like this
star this property tabling member
155
star this property label Biography information for Geraint Davies more like this
1124918
star this property registered interest false more like this
star this property date less than 2019-05-07more like thismore than 2019-05-07
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Haemophilia: Medical Treatments more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that haemophilia patients receive (a) appropriate access to physiotherapy, (b) a regular clinical review, and (c) tailored dosing of treatments in accordance with NHS England’s service specification. more like this
star this property tabling member constituency Strangford more like this
star this property tabling member printed
Jim Shannon more like this
star this property uin 251321 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-15more like thismore than 2019-05-15
star this property answer text <p>Regular clinical reviews of patients with severe and moderate haemophilia and access to physiotherapy services are specified within the service specification for haemophilia which is available at the following link:</p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf</a></p><p>In addition, the Haemophilia Quality Dashboard has a metric specifically in relation to the proportion of severe Haemophilia patients who have had an annual review. Where local commissioning teams are made aware that haemophilia patients do not have access to appropriate care then local action plans will be agreed to rectify this.</p><p>The service specification for haemophilia currently does not require that haemophilia patients receive tailored dosing of treatment. However, commissioners consider that this would represent good practice. NHS England has supported clinical teams to provide tailored dosing, within the parameters of the agreed commissioning criteria and guidelines, by making a wide range of products available for reimbursement.</p><p>To date, all licensed and currently marketed products for haemophilia are available for reimbursement. Some products have been limited to Haemophilia Comprehensive Care Centres due to specific requirements for supporting services and expertise (these are products for patients with inhibitors).</p><p>NHS England wants all patients with lifelong conditions to be engaged in the management of their condition. NHS England, in conjunction with the United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO), believes that tools like Haemtrack are useful in achieving this aim. NHS England is aware of evidence that indicates, but does not confirm, that patients who use Haemtrack have better clinical outcomes than patients who do not. NHS England supports UKHCDO via the National Haemophilia Database to provide further data and evidence demonstrating the value and clinical benefits of Haemtrack.</p><p>The Commercial Medicines Unit has two national framework agreements in place that provide access to recombinant factor VIII (rFVIII) haemophilia products. The one licensed Extended Half Life-Factor VIII product available in the UK has been funded since September 2016 and a significant number of patients are now treated with this product. NHS England and other UK Health Commissioners work closely with clinicians and patient representatives to ensure that the frameworks continue to meet clinical need whilst delivering good value to the National Health Service.</p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property grouped question UIN
251322 more like this
251323 more like this
251324 more like this
star this property question first answered
less than 2019-05-15T16:14:44.547Zmore like thismore than 2019-05-15T16:14:44.547Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4131
star this property label Biography information for Jim Shannon more like this
1124919
star this property registered interest false more like this
star this property date less than 2019-05-07more like thismore than 2019-05-07
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Haemophilia: Medical Treatments more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect of the Commercial Medicines Unit’s national tender framework for factor VIII haemophilia products on patient access to extended half-life medicines. more like this
star this property tabling member constituency Strangford more like this
star this property tabling member printed
Jim Shannon more like this
star this property uin 251322 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-15more like thismore than 2019-05-15
star this property answer text <p>Regular clinical reviews of patients with severe and moderate haemophilia and access to physiotherapy services are specified within the service specification for haemophilia which is available at the following link:</p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf</a></p><p>In addition, the Haemophilia Quality Dashboard has a metric specifically in relation to the proportion of severe Haemophilia patients who have had an annual review. Where local commissioning teams are made aware that haemophilia patients do not have access to appropriate care then local action plans will be agreed to rectify this.</p><p>The service specification for haemophilia currently does not require that haemophilia patients receive tailored dosing of treatment. However, commissioners consider that this would represent good practice. NHS England has supported clinical teams to provide tailored dosing, within the parameters of the agreed commissioning criteria and guidelines, by making a wide range of products available for reimbursement.</p><p>To date, all licensed and currently marketed products for haemophilia are available for reimbursement. Some products have been limited to Haemophilia Comprehensive Care Centres due to specific requirements for supporting services and expertise (these are products for patients with inhibitors).</p><p>NHS England wants all patients with lifelong conditions to be engaged in the management of their condition. NHS England, in conjunction with the United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO), believes that tools like Haemtrack are useful in achieving this aim. NHS England is aware of evidence that indicates, but does not confirm, that patients who use Haemtrack have better clinical outcomes than patients who do not. NHS England supports UKHCDO via the National Haemophilia Database to provide further data and evidence demonstrating the value and clinical benefits of Haemtrack.</p><p>The Commercial Medicines Unit has two national framework agreements in place that provide access to recombinant factor VIII (rFVIII) haemophilia products. The one licensed Extended Half Life-Factor VIII product available in the UK has been funded since September 2016 and a significant number of patients are now treated with this product. NHS England and other UK Health Commissioners work closely with clinicians and patient representatives to ensure that the frameworks continue to meet clinical need whilst delivering good value to the National Health Service.</p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property grouped question UIN
251321 more like this
251323 more like this
251324 more like this
star this property question first answered
less than 2019-05-15T16:14:44.61Zmore like thismore than 2019-05-15T16:14:44.61Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4131
star this property label Biography information for Jim Shannon more like this
1124920
star this property registered interest false more like this
star this property date less than 2019-05-07more like thismore than 2019-05-07
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Blood Diseases: Medical Treatments more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what steps he NHS England is taking to ensure that patients with bleeding disorders have adequate access to treatment options that meet individual patient need. more like this
star this property tabling member constituency Strangford more like this
star this property tabling member printed
Jim Shannon more like this
star this property uin 251323 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-15more like thismore than 2019-05-15
star this property answer text <p>Regular clinical reviews of patients with severe and moderate haemophilia and access to physiotherapy services are specified within the service specification for haemophilia which is available at the following link:</p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf</a></p><p>In addition, the Haemophilia Quality Dashboard has a metric specifically in relation to the proportion of severe Haemophilia patients who have had an annual review. Where local commissioning teams are made aware that haemophilia patients do not have access to appropriate care then local action plans will be agreed to rectify this.</p><p>The service specification for haemophilia currently does not require that haemophilia patients receive tailored dosing of treatment. However, commissioners consider that this would represent good practice. NHS England has supported clinical teams to provide tailored dosing, within the parameters of the agreed commissioning criteria and guidelines, by making a wide range of products available for reimbursement.</p><p>To date, all licensed and currently marketed products for haemophilia are available for reimbursement. Some products have been limited to Haemophilia Comprehensive Care Centres due to specific requirements for supporting services and expertise (these are products for patients with inhibitors).</p><p>NHS England wants all patients with lifelong conditions to be engaged in the management of their condition. NHS England, in conjunction with the United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO), believes that tools like Haemtrack are useful in achieving this aim. NHS England is aware of evidence that indicates, but does not confirm, that patients who use Haemtrack have better clinical outcomes than patients who do not. NHS England supports UKHCDO via the National Haemophilia Database to provide further data and evidence demonstrating the value and clinical benefits of Haemtrack.</p><p>The Commercial Medicines Unit has two national framework agreements in place that provide access to recombinant factor VIII (rFVIII) haemophilia products. The one licensed Extended Half Life-Factor VIII product available in the UK has been funded since September 2016 and a significant number of patients are now treated with this product. NHS England and other UK Health Commissioners work closely with clinicians and patient representatives to ensure that the frameworks continue to meet clinical need whilst delivering good value to the National Health Service.</p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property grouped question UIN
251321 more like this
251322 more like this
251324 more like this
star this property question first answered
less than 2019-05-15T16:14:44.657Zmore like thismore than 2019-05-15T16:14:44.657Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4131
star this property label Biography information for Jim Shannon more like this
1124921
star this property registered interest false more like this
star this property date less than 2019-05-07more like thismore than 2019-05-07
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Haemophilia: Medical Treatments more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, whether NHS England has made an assessment of the adequacy of the availability of Haemtrack in Haemophilia centres. more like this
star this property tabling member constituency Strangford more like this
star this property tabling member printed
Jim Shannon more like this
star this property uin 251324 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-15more like thismore than 2019-05-15
star this property answer text <p>Regular clinical reviews of patients with severe and moderate haemophilia and access to physiotherapy services are specified within the service specification for haemophilia which is available at the following link:</p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf</a></p><p>In addition, the Haemophilia Quality Dashboard has a metric specifically in relation to the proportion of severe Haemophilia patients who have had an annual review. Where local commissioning teams are made aware that haemophilia patients do not have access to appropriate care then local action plans will be agreed to rectify this.</p><p>The service specification for haemophilia currently does not require that haemophilia patients receive tailored dosing of treatment. However, commissioners consider that this would represent good practice. NHS England has supported clinical teams to provide tailored dosing, within the parameters of the agreed commissioning criteria and guidelines, by making a wide range of products available for reimbursement.</p><p>To date, all licensed and currently marketed products for haemophilia are available for reimbursement. Some products have been limited to Haemophilia Comprehensive Care Centres due to specific requirements for supporting services and expertise (these are products for patients with inhibitors).</p><p>NHS England wants all patients with lifelong conditions to be engaged in the management of their condition. NHS England, in conjunction with the United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO), believes that tools like Haemtrack are useful in achieving this aim. NHS England is aware of evidence that indicates, but does not confirm, that patients who use Haemtrack have better clinical outcomes than patients who do not. NHS England supports UKHCDO via the National Haemophilia Database to provide further data and evidence demonstrating the value and clinical benefits of Haemtrack.</p><p>The Commercial Medicines Unit has two national framework agreements in place that provide access to recombinant factor VIII (rFVIII) haemophilia products. The one licensed Extended Half Life-Factor VIII product available in the UK has been funded since September 2016 and a significant number of patients are now treated with this product. NHS England and other UK Health Commissioners work closely with clinicians and patient representatives to ensure that the frameworks continue to meet clinical need whilst delivering good value to the National Health Service.</p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property grouped question UIN
251321 more like this
251322 more like this
251323 more like this
star this property question first answered
less than 2019-05-15T16:14:44.703Zmore like thismore than 2019-05-15T16:14:44.703Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4131
star this property label Biography information for Jim Shannon more like this
1124922
star this property registered interest false more like this
star this property date less than 2019-05-07more like thismore than 2019-05-07
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Haemophilia: Medical Treatments more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, if he will make it his policy that NHS England include haemophilia as a condition area in the Getting It Right First Time programme. more like this
star this property tabling member constituency Strangford more like this
star this property tabling member printed
Jim Shannon more like this
star this property uin 251325 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-15more like thismore than 2019-05-15
star this property answer text <p>The Getting It Right First Time (GIRFT) programme aims to drive improvements in medical and surgical specialties through clinical leadership and the use of data to identify and reduce unwarranted variation in practice. By tackling variations in the way services are delivered across the National Health Service, and by sharing best practice between trusts, GIRFT identifies changes that will help improve care and patient outcomes, as well as delivering efficiencies such as the reduction of unnecessary procedures and cost savings.</p><p>Although there are no specific plans to include haemophilia as a condition area in the GIRFT programme currently, the ambition is that GIRFT will continue to expand to other medical specialities. Currently, areas are prioritised based on opportunity for improvements in patient care, suspected degree of variation and wide strategic priorities. Some examples of these work streams are lung cancer, paediatric critical care and neonatal intensive care.</p> more like this
star this property answering member constituency Wimbledon more like this
star this property answering member printed Stephen Hammond more like this
star this property question first answered
less than 2019-05-15T10:49:41.443Zmore like thismore than 2019-05-15T10:49:41.443Z
star this property answering member
1585
star this property label Biography information for Stephen Hammond more like this
star this property tabling member
4131
star this property label Biography information for Jim Shannon more like this
1124923
star this property registered interest false more like this
star this property date less than 2019-05-07more like thismore than 2019-05-07
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Hospitals: Infectious Diseases more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 20 March 2019 to Question 231466 on Hospitals: Infectious Diseases, whether work of Public Health England will also include as assessment of the effect of changes to ophthalmic surgical practice on trends in the level of risk of infection rates in hospitals. more like this
star this property tabling member constituency Strangford more like this
star this property tabling member printed
Jim Shannon more like this
star this property uin 251326 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-15more like thismore than 2019-05-15
star this property answer text <p>Public Health England does not currently include ophthalmic surgery as part of mandatory or voluntary surveillance of surgical site infections.</p> more like this
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property question first answered
less than 2019-05-15T16:24:36.63Zmore like thismore than 2019-05-15T16:24:36.63Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4131
star this property label Biography information for Jim Shannon more like this